IKT

SEC source: 0001193125-26-328467 · ownership.xml · derivative · entry 2

BERMAN DENNIS N · CIK 0001273858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,854 shares

Expires 2026-08-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The options are fully vested and exercisable.

SEC source: 0001193125-26-328467 · ownership.xml · nonDerivative · entry 1

BERMAN DENNIS N · CIK 0001273858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,854

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001231919-26-000815 · form4-07312026_080714.xml · derivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 18,030,000

Underlying: Common Stock · 18,030,000 shares

Expires not disclosed

F1 · kind: On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").

F1 · price: On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").

F4 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F4 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001231919-26-000815 · form4-07312026_080714.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · 10% owner

Kolchinsky Peter · CIK 0001384859 · 10% owner

Shah Rajeev M. · CIK 0001619841 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 6,970,000

F1 · kind: On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").

F1 · price: On July 29, 2026, RA Capital Healthcare Fund, L.P. (the "Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the "Pre-Funded Warrant").

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Held directly by the Fund.

SEC source: 0001193125-26-290476 · ownership.xml · derivative · entry 1

Canner David · CIK 0002041173 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-06-26

F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0001193125-26-290477 · ownership.xml · derivative · entry 1

BERMAN DENNIS N · CIK 0001273858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-06-26

F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0001193125-26-290475 · ownership.xml · derivative · entry 1

Kush Arvind · CIK 0001986806 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-06-26

F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0001193125-26-290474 · ownership.xml · derivative · entry 1

Bellini Roberto · CIK 0001802453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-06-26

F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0001193125-26-290472 · ownership.xml · derivative · entry 1

Aurentz Vincent · CIK 0001657494 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-06-26

F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0001193125-26-290470 · ownership.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,000

Underlying: Common Stock · 155,000 shares

Expires 2036-06-26

F1 · derivative.exercise_date: The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0001193125-26-068079 · ownership.xml · nonDerivative · entry 1

Aurentz Vincent · CIK 0001657494 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 510,596

F1 · shares: As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

F1 · balance_after: As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

SEC source: 0001193125-26-068077 · ownership.xml · nonDerivative · entry 1

Cabell Christopher · CIK 0001814928 · President & Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 676,564

F1 · shares: As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

F1 · balance_after: As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

SEC source: 0001193125-26-068063 · ownership.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,176

F1 · shares: As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

F1 · balance_after: As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.

SEC source: 0001193125-26-006351 · ownership.xml · derivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,982,706

Underlying: Common Stock · 4,982,706 shares

Expires 2036-01-05

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

SEC source: 0001193125-26-006350 · ownership.xml · derivative · entry 1

Cabell Christopher · CIK 0001814928 · President & Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 900,117

Underlying: Common Stock · 900,117 shares

Expires 2036-01-05

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

SEC source: 0001193125-26-006343 · ownership.xml · derivative · entry 1

McIntyre David · CIK 0001404254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 986,319

Underlying: Common Stock · 986,319 shares

Expires 2036-01-05

F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

SEC source: 0001875620-25-000025 · primary_doc.xml · nonDerivative · entry 1

Sands Capital Life Sciences Pulse Fund II, L.P. · CIK 0001875620 · 10% owner

Sands Capital Alternatives, LLC · CIK 0001846444 · 10% owner

SANDS FRANK M. · CIK 0001870494 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,018,965

F5 · kind: The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share.

F1 · balance_after: This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the "Series A-1 Warrant") or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the "Series B-1 Warrant"), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. ("Sands Pulse Fund II"), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the "Purchase Agreement").

F2 · balance_after: (Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the "Warrant Initial Registration Statement") if the Securities and Exchange Commission ("SEC") notifies the Issuer that it will "review" the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be "reviewed" or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the "Initial Exercise Date"). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable,

F3 · balance_after: (Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.

F4 · ownership.direct: Represents shares of common stock, par value $0.001, of the Issuer ("Common Stock") held by Sands Pulse Fund II. Sands Capital Alternatives, LLC ("Sands Alternatives") is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. ("Sands Pulse GP L.P.") is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC ("Sands Pulse GP LLC") is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0000950170-25-093434 · ownership.xml · derivative · entry 1

Canner David · CIK 0002041173 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,176

Underlying: Common Stock · 108,176 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0000950170-25-093432 · ownership.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,176

Underlying: Common Stock · 108,176 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0000950170-25-093436 · ownership.xml · derivative · entry 1

Aurentz Vincent · CIK 0001657494 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,176

Underlying: Common Stock · 108,176 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0000950170-25-093428 · ownership.xml · derivative · entry 1

BERMAN DENNIS N · CIK 0001273858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,176

Underlying: Common Stock · 108,176 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0000950170-25-093430 · ownership.xml · derivative · entry 1

Kush Arvind · CIK 0001986806 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,176

Underlying: Common Stock · 108,176 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0000950170-25-093424 · ownership.xml · derivative · entry 1

Bellini Roberto · CIK 0001802453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,176

Underlying: Common Stock · 108,176 shares

Expires 2032-06-30

F1 · derivative.exercise_date: The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

SEC source: 0000950170-25-054712 · ownership.xml · derivative · entry 1

McIntyre David · CIK 0001404254 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,775,539

Underlying: Common Stock · 1,775,539 shares

Expires 2035-04-14

F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on April 14, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment on each such vesting date.

SEC source: 0000950170-25-026652 · ownership.xml · derivative · entry 1

Cabell Christopher · CIK 0001814928 · President & Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,100,705

Underlying: Common Stock · 1,100,705 shares

Expires 2035-02-21

F1 · derivative.exercise_date: The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

SEC source: 0000950170-25-026650 · ownership.xml · derivative · entry 1

Aurentz Vincent · CIK 0001657494 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,427

Underlying: Common Stock · 134,427 shares

Expires 2035-02-21

F1 · derivative.exercise_date: The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

SEC source: 0000950170-25-026627 · ownership.xml · derivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 602,346

Underlying: Common Stock · 602,346 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date.

SEC source: 0000950170-25-093445 · ownership.xml · derivative · entry 1

Cabell Christopher · CIK 0001814928 · President & Head of R&D

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,100,705

Underlying: Common Stock · 1,100,705 shares

Expires 2035-02-21

F1 · derivative.exercise_price: The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.

F2 · derivative.exercise_date: The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

SEC source: 0000950170-25-093440 · ownership.xml · derivative · entry 1

Aurentz Vincent · CIK 0001657494 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,427

Underlying: Common Stock · 134,427 shares

Expires 2035-02-21

F1 · derivative.exercise_price: The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported an incorrect exercise price with respect to the stock option award originally granted on February 21, 2025. This amendment is being filed solely to correct the exercise price.

F2 · derivative.exercise_date: The options will vest and become exercisable in two substantially equal installments on the first and second anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.

SEC source: 0000950170-25-093441 · ownership.xml · derivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 602,346

Underlying: Common Stock · 602,346 shares

Expires 2035-02-21

F1 · derivative.exercise_price: The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the "Option Award"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award.

F2 · derivative.exercise_date: The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 21, 2025, subject to the Reporting Person's continued employment through such date.

F1 · derivative.expiration_date: The Reporting Person's Form 4 filed with the SEC on February 25, 2025 inadvertently reported the incorrect exercise price and expiration date with respect to the stock option award originally granted on February 21, 2025 (the "Option Award"). This amendment is being filed solely to correct the exercise price and expiration date of the Option Award.

SEC source: 0001193125-25-191463 · ownership.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,265

F1 · shares: Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 9,544 shares vested on the Closing Date, 28,632 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 19,089 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 19,089 shares shall be forfeited.

SEC source: 0000950170-25-023600 · ownership.xml · derivative · entry 2

Iwicki Mark T · CIK 0001415537 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,794,291

Underlying: Common Stock · 1,794,291 shares

Expires 2035-02-17

F1 · derivative.exercise_date: The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date.

SEC source: 0000950170-25-023583 · ownership.xml · derivative · entry 2

Canner David · CIK 0002041173 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,585

Underlying: Common Stock · 116,585 shares

Expires 2035-02-14

F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

SEC source: 0000950170-25-023583 · ownership.xml · derivative · entry 1

Canner David · CIK 0002041173 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,640

Underlying: Common Stock · 22,640 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025.

SEC source: 0000950170-25-023600 · ownership.xml · derivative · entry 1

Iwicki Mark T · CIK 0001415537 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373,857

Underlying: Common Stock · 4,373,857 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options will vest and become exercisable in 48 substantially equal monthly installments beginning on March 12, 2025, subject to the Reporting Person's continued employment through such date.

SEC source: 0000950170-25-023595 · ownership.xml · derivative · entry 2

Kush Arvind · CIK 0001986806 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,585

Underlying: Common Stock · 116,585 shares

Expires 2035-02-14

F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

SEC source: 0000950170-25-023595 · ownership.xml · derivative · entry 1

Kush Arvind · CIK 0001986806 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,600

Underlying: Common Stock · 56,600 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025.

SEC source: 0000950170-25-023594 · ownership.xml · derivative · entry 2

Bellini Roberto · CIK 0001802453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,585

Underlying: Common Stock · 116,585 shares

Expires 2035-02-14

F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

SEC source: 0000950170-25-023594 · ownership.xml · derivative · entry 1

Bellini Roberto · CIK 0001802453 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,580

Underlying: Common Stock · 73,580 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025.

SEC source: 0000950170-25-023592 · ownership.xml · derivative · entry 1

Freeman Roy Lester · CIK 0001799732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,640

Underlying: Common Stock · 22,640 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025.

SEC source: 0000950170-25-023565 · ownership.xml · derivative · entry 1

BERMAN DENNIS N · CIK 0001273858 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,620

Underlying: Common Stock · 39,620 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025.

SEC source: 0000950170-25-023586 · ownership.xml · derivative · entry 2

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 116,585

Underlying: Common Stock · 116,585 shares

Expires 2035-02-14

F2 · derivative.exercise_date: The options will vest and become exercisable in two equal annual installments on October 24, 2025 and October 24, 2026.

SEC source: 0000950170-25-023586 · ownership.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,600

Underlying: Common Stock · 56,600 shares

Expires 2035-02-14

F1 · derivative.exercise_date: The options vested and became exercisable on February 14, 2025.

SEC source: 0000950170-25-007746 · ownership.xml · derivative · entry 4

Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2031-04-01

F1 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-007746 · ownership.xml · derivative · entry 3

Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 90,000 shares

Expires 2031-04-01

F1 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-007746 · ownership.xml · derivative · entry 2

Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,834

Underlying: Common Stock · 5,834 shares

Expires 2029-11-28

F1 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-007746 · ownership.xml · derivative · entry 1

Lees-Rolfe Garth · CIK 0002017374 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,834 shares

Expires 2029-11-28

F1 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F1 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 12

Freeman Roy Lester · CIK 0001799732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-07-16

F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 11

Freeman Roy Lester · CIK 0001799732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2031-07-16

F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

SEC source: 0000950170-25-007742 · ownership.xml · derivative · entry 10

Freeman Roy Lester · CIK 0001799732 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires 2030-06-30

F2 · kind: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F2 · price: The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

F3 · derivative.exercise_date: This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.